as of 11-12-2026 3:50pm EST
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
| Founded: | 1897 | Country: | United States |
| Employees: | N/A | City: | FRANKLIN LAKES |
| Market Cap: | 54.6B | IPO Year: | 1999 |
| Target Price: | $226.14 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | monthly | |
| EPS: | 1.59 | EPS Growth: | -0.68 |
| 52 Week Low/High: | $140.11 - $216.74 | Next Earning Date: | 11-05-2026 |
| Revenue: | $21,840,000,000 | Revenue Growth: | 8.24% |
| Revenue Growth (this year): | 1.74% | Revenue Growth (next year): | 4.24% |
| P/E Ratio: | 134.67 | Index: | |
| Free Cash Flow: | 3.9B | FCF Growth: | +3.67% |
Chairman, CEO and President
Avg Cost/Share
$210.00
Shares
2,993
Total Value
$628,530.00
Owned After
110,163
SEC Form 4
EVP, Chief Revenue Officer
Avg Cost/Share
$198.13
Shares
76
Total Value
$15,057.88
Owned After
19,568
SEC Form 4
EVP, Chief Revenue Officer
Avg Cost/Share
$188.49
Shares
165
Total Value
$31,100.85
Owned After
19,568
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Polen Thomas E Jr | BDX | Chairman, CEO and President | Nov 5, 2026 | Sell | $210.00 | 2,993 | $628,530.00 | 110,163 | |
| Feld Michael | BDX | EVP, Chief Revenue Officer | Oct 26, 2026 | Sell | $198.13 | 76 | $15,057.88 | 19,568 | |
| Feld Michael | BDX | EVP, Chief Revenue Officer | Aug 26, 2026 | Sell | $188.49 | 165 | $31,100.85 | 19,568 |
SEC 8-K filings with transcript text
Nov 5, 2026 · 100% conf.
1D
-2.77%
$203.40
Act: -0.48%
5D
-3.52%
$201.83
20D
-2.98%
$202.96
2 ex9919302026.htm
Document
*Exhibit 99.1
1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com
Contacts:
Investors: Shawn Bevec, SVP, Investor Relations - investor.relations@bd.com
Media: Matt Marcus, VP, Public Relations - matt.marcus@bd.com
BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
•Q4 revenue of $5.3 billion increased 5.4% as reported, 5.6% FXN
•Q4 GAAP and adjusted diluted EPS of $2.52 and $4.15, respectively
•FY26 revenue of $19.5 billion increased 4.9% as reported, 3.9% FXN
•FY26 GAAP and adjusted diluted EPS of $5.06 and $12.70, respectively
•FY26 cash from continuing operations increased 30.0% to $3.6 billion and free cash flow increased 42.5% to $2.9 billion
•Company issues FY27 guidance
FRANKLIN LAKES, NJ (November 5, 2026) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 fourth quarter and full year, which ended September 30, 2026.
"We delivered a strong fourth quarter, with 5.6% revenue growth and broad-based performance led by our key growth platforms," said Tom Polen, chairman, CEO and president of BD. "Fiscal 2026 was a defining year as we completed BD's transformation to a more focused MedTech company with separation of our Life Sciences business. We strengthened our core growth and expanded BD Excellence to elevate our commercial capabilities, accelerate innovation and drive greater productivity. We enter fiscal 2027 from a position of strength, with a portfolio built for durable performance and confidence in the long-term growth, earnings and cash-flow potential of New BD."
Recent Business Highlights
•BD announced a landmark partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for America's essential medical consumables.
•Through this partnership, BD intends to invest $19 billion in the U.S. over several years, including capital, operational and supply chain investments, with $3 billion directed toward manufacturing expansion.
•The agreement also provides relief from future tariffs imposed under Section 232 on covered BD products and inputs, subject to the final scope and implementation of any future Section 232 actions and BD's achievement of agreed milestones.
•Connected Care:
•Announced that Fairview Health Services is the first health system in the U.S. to deploy the BD® Vmax™ 160 Pharmacy Automation Robot, a next-generation solution that expands beyond traditional dispensing to manage specialty therapies and refrigerated medications in high-volume, centralized outpatient pharmacy operations.
Page 1
•Interventional:
•Strengthened its leadership in peripheral vascular innovation:
•Announced the BD® Liverty™ TIPS Stent Graft U.S. launch, advancing portal hypertension care with a next‑generation interventional solution for patients with advanced liver disease, building on established clinical and physician experience in Europe and supported by six-month interim results from the ARCH clinical study.
•Announced positive nine-month results from the iliac cohort of the AGILITY clinical trial of the BD® Revello™ Vascular Covered Stent, with data demonstrating high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease.
•Announced significant milestones in its advanced tissue regeneration strategy and expansion efforts:
•Surpassed the first enrollment milestone in the STANCE clinical trial evaluating BD® GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture and malposition, the most frequent complication of implant-based breast surgery.
•Completed enrollment in the landmark PREVENT clinical trial, the first large-scale randomized study evaluating BD® Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery.
The company will hold its 2026 Investor Day on December 10th at the New York Stock Exchange. Additional information will be forthcoming.
Basis of Presentation— Continuing Operations
On February 9, 2026, the company completed the spin-off of BD's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation ("Waters"). The historical results of the former Biosciences and Diagnostic Solutions business, which was previously the Life Sciences segment, are reflected as discontinued operations for all periods presented. Financial information presented in this release reflects BD's results on a continuing operations basis. Prior periods have been recast to conform to this presentation.
Fourth Quarter Fiscal 2026 Operating Results
(Millions of dollars, except per share amounts)Three Months Ended September 30,Reported Change Foreign Currency Neutral Change1
20262025
Revenues$5,274 $5,005 5.4 %5.6 %
Reported Diluted Earnings per Share$2.52 $
Aug 6, 2026 · 100% conf.
1D
+1.08%
$178.98
Act: -0.12%
5D
+3.09%
$182.54
20D
+2.57%
$181.62
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1786061739.e0aafa20
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
May 7, 2026 · 100% conf.
1D
-2.79%
$148.98
Act: -2.52%
5D
-3.32%
$148.17
Act: -5.74%
20D
-3.19%
$148.38
Act: -1.37%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1784665128.25cfcf0e
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
See how BDX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "BDX Becton Dickinson and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.